Researchers sought to determine whether combination decitabine, venetoclax, and ponatinib would be effective in patients with accelerated phase CML.

Atezolizumab did not improve overall survival, progression-free survival, distant metastasis-free survival, or time to local failure.

Improved three-year disease-free and recurrence-free survival seen with intensive chemotherapy regimen. HealthDay News — For patients with operative triple-negative breast cancer, a multigene ...

Higher peak doses were associated with inferior progression-free survival and overall survival. Cancer patients may fare better if they receive lower corticosteroid doses to treat immune-related ...